DBL-583

In today's article we are going to delve into the fascinating world of DBL-583. This topic, which has captured the attention of experts and enthusiasts alike, offers us a wide range of interesting aspects to explore. From its impact on society to its relevance today, DBL-583 is a topic that continues to generate debate and discussion. Throughout this article, we will try to shed light on the different aspects and perspectives surrounding DBL-583, with the aim of providing a more complete and enriching vision of its importance. So get ready to immerse yourself in the exciting universe of DBL-583 and discover everything this theme has to offer.

DBL-583
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC38H50F2N2O3
Molar mass620.826 g·mol−1
3D model (JSmol)
  • CCCCCCCCCC(=O)OC(CCN1CCN(CC1)CCOC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C4=CC=CC=C4
  • InChI=1S/C38H50F2N2O3/c1-2-3-4-5-6-7-11-14-37(43)45-36(31-12-9-8-10-13-31)23-24-41-25-27-42(28-26-41)29-30-44-38(32-15-19-34(39)20-16-32)33-17-21-35(40)22-18-33/h8-10,12-13,15-22,36,38H,2-7,11,14,23-30H2,1H3 ☒N
  • Key:IXQPQADYPIEKQC-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

DBL-583 is a selective dopamine reuptake inhibitor of the piperazine chemical class.[1] It is the decanoate ester of a hydroxy vanoxerine.[1] DBL-583 breaks down very slowly in the body, lasting for up to a month after a single injection.[1]

See also

References

  1. ^ a b c Baumann MH, Phillips JM, Ayestas MA, Ali SF, Rice KC, Rothman RB (June 2002). "Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence". Annals of the New York Academy of Sciences. 965 (1): 92–108. Bibcode:2002NYASA.965...92B. doi:10.1111/j.1749-6632.2002.tb04154.x. PMID 12105088. S2CID 27275723.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.